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primary interactions of the hormones with their speciﬁc nuclear re-
ceptor proteins. Formation of nuclear co-activator or co-repressor
complexes involving the liganded receptors subsequently result in
transcriptional eventsdeither activation or suppressiondat genes
that are speciﬁc targets of thyroid hormone or steroids. Nongenomic
actions of thyroid hormone and steroids are in contrast initiated at
binding sites on the plasma membrane or in cytoplasm or organelles
and do not primarily require formation of intranuclear receptor
protein-hormone complexes. Importantly, hormonal actions that
begin nongenomically outside the nucleus often culminate in changes
innuclear transcriptional events that are regulatedby both traditional
intranuclear receptors aswell as other nuclear transcription factors. In
the case of thyroid hormone, the extranuclear receptor can be the
classical “nuclear” thyroid receptor (TR), aTR isoform,or integrinavb3.
In the caseof steroidhormones, themembrane receptor is usually, but
not always, the classical “nuclear” steroid receptor. This concept de-
ﬁnes theparadigmof overlappingnongenomicandgenomichormone
mechanisms of action. Here we review some examples of how
extranuclear signaling by thyroid hormone and by estrogens and an-
drogens modulates intranuclear hormone signaling to regulate a
number of vital biological processes both in normal physiology and in
cancer progression. We also point out that nongenomic actions of
thyroid hormonemay mimic effects of estrogen in certain tumors.
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S.R. Hammes, P.J. Davis / Best Practice & Research Clinical Endocrinology & Metabolism 29 (2015) 581e593582IntroductionThyroid hormone and steroids have been viewed as having two distinct signaling pathways: the
nongenomic transcription-independent pathway that occurs outside the nucleus and the genomic
transcription-dependent pathway that occurs inside the nucleus. In the past decade, however, thyroid
hormones and steroid hormones both have been found to exploit interfaces or interactions of both
their genomic and nongenomic mechanisms of actions, suggesting that genomic and nongenomic
signaling are not always parallel processes, but are very often sequential. In some instances, thyroid
and steroid hormone signaling appear to overlap. For example, nongenomic thyroid hormone signaling
can activate the nuclear estrogen receptor (ERa) in breast cancer [1] and lung cancer cells [2], and ERa
expression by thyroid carcinoma has been claimed to alter course of the cancer [3].
In this review, we examine separately the overlaps of nongenomic and genomic actions of thyroid
hormone and of steroids as well as the overlaps or interfaces of certain thyroid hormone and steroid
actions. We emphasize possible clinical consequences of these relationships.
Overlapping genomic and nongenomic actions of thyroid hormone
The mechanism of genomic actions of thyroid hormone is well deﬁned and has been extensively
reviewed [4,5]. It requires binding by nuclear thyroid hormone receptor (TR) proteins of 3,5,30-triiodo-
L-thyronine (T3) and the formation of transcriptionally active complexes with nuclear co-activator
proteins such as p300 and steroid receptor co-activator-1 (SRC-1) [6]. The complexes bind to pro-
moter regions of thyroid hormone-responsive genes to promote mRNA transcription. The transcripts
are then translated into gene products (proteins) in endoplasmic reticulum.
Nongenomic, or transcription-independent, actions of thyroid hormone are initiated at a speciﬁc
receptor on a cell surface protein (integrin avb3) [7] or at truncated isoforms of nuclear receptor TRa at
the plasma membrane or in cytoplasm [4,8] (see below) [8]. The hormone also acts nongenomically on
mitochondria via another TR isoform [9].When signaling through avb3, thyroid hormone can act locally
within the plasmamembrane at transporter systems [10], can be extracellulardmanifested at vascular
growth factor receptors adjacent to the integrin [11]dor can be intracellular. Intracellular signals
include regulation from integrin avb3 of trafﬁcking of speciﬁc proteins from cytoplasm into the nuclear
compartment [12], or activation of signal transducing kinasesde.g., mitogen-activated protein kinase
(MAPK, or extracellular regulated kinase 1/2, ERK1/2) and Aktdwhose downstream targets include
nucleoproteins [13] and transcription factors that regulate expression of genes encoding for important
regulatory proteins such as hypoxia-inducible factor-1a (HIF-1a) [14], basic ﬁbroblast growth factor
(bFGF; FGF2) [15], matrix metalloproteinase-9 (MMP-9) [16] and certain oncogenes [17] or proto-
oncogenes [18]. Importantly, these thyroid hormone-mediated effects are initiated at the membrane
and are then transduced into nuclear events, all independent of classical thyroid hormone receptors.
It is also important to note that the afﬁnity of the thyroid hormone receptor on avb3 is signiﬁcantly
higher for T4 than for T3 [19], in contrast to hormone afﬁnities at TR [4]. A TRa isoform (TRDa1) outside
the nucleus is involved in maintenance of the actin cytoskeleton by T4 and reverse T3 [4], and the
p30 TRa1 isoform has been identiﬁed in the plasma membrane, from which T3 may regulate prolif-
eration of nonmalignant cells via ERK and Akt [8]; however, these TR isoforms that may be found in
cytoplasma or at the plasma memrane share no structural homologies with the hormone receptor on
the integrin and are unrelated to the transcriptional events described above.
Overlapping nongenomic and genomic actions of thyroid hormone are also apparent between
integrins and classical thyroid hormone receptor. For example, thyroid hormone binding to avb3 at the
membrane regulates TRb1 shuttling from the cytoplasm to the nucleus [12]. T4 is bound to the S2
domain of TRb1 that recognizes both T4 and T3 [14]. This process requires complexing in the cytoplasm
of MAPK and TRb1, after which TR is phosphorylated in the course of its nuclear importation.
Pharmacologic inhibition of mitogen-activated protein kinase kinase (MEK) prevents nuclear uptake
of both TRb1 and MAPK. At the S1 domain of the integrin, only T3 is a ligand and it induces
cytoplasm-to-nucleus transfer of TRa1 [14]. These observations indicate discrete control at avb3 for
the nuclear uptake of intact TRa1 and TRb1dwhich is desirable in light of the separate functions of
these two nuclear receptors [4].
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modulation of expression of the TRb1 gene itself. This became apparent when T4 was shown tomediate
internalization of avb3 [20]. T4 is not transported into the cell with the internalized integrin and, within
the cell, the av and b3 monomers have disparate fates. The phosphorylated av monomer, but not b3, is
recovered in the nucleus in thyroid hormone-treated cells in a monomer-MAPK-p300 complex. The
complex binds to the promoter region of a panel of genes, including TRb1, ERa and cyclooxygenase-2
(COX-2) [21] and increases expression of each of these genes. Thus, this nongenomic process of avb3
internalization in response toT4 supports genomic actions of T3 by increasing availability of nuclear TR.
In addition, nongenomic T4 action at the integrin overlaps genomic effects of estrogen by increasing
availability of nuclear ERa. As mentioned above, nuclear ERa is also a target of activation by thyroid
hormone [1]. With regard to COX-2, its expression is widely regarded as a biomarker of aggressiveness
in a variety of tumors. However, a stilbene, resveratrol, causes nuclear accumulation of COX-2 protein
that initiates a process of p53-dependent apoptosis in cancer cells [22]. Thyroid hormone blocks this
action of resveratrol [22,23], supporting the role of the hormone in tumor cells as an anti-apoptotic
agent [22,24]. Thus, the thyroid hormone receptor on avb3 directs overlapping nongenomic and
genomic actions of thyroid hormone, may serve to modulate genomic actions of estrogen, and is a
contributor to regulation of the complex process of apoptosis.
In addition to regulating TRb1 expression, T4 via avb3 regulates post-translational modiﬁcations of
TRb1. For example, T4 triggers MAPK-dependent phosphorylation of TRb1 within 10e20 min of
exposure of cells to the hormone [25]. Ser-142 of TR is the target of MAPK-dependent phosphorylation,
and a MAPK docking site has been identiﬁed on the thyroid hormone receptor [26]. Speciﬁc serine
phosphorylation of TRb1 causes shedding by the receptor of corepressor proteins (SMRT) and
recruitment of co-activators, e.g., p300, that contribute to the transcriptional activity of the hormone-
liganded receptor. Acting at the plasma membrane, presumptively via avb3, T4 also regulates the
phosphorylation of ERa [1] (see below).
Besides regulating TR phosphorylation, T4 also nongenomically induces acetylation of the thyroid
hormone receptor [6]. The acetylation step is carried out by SRC-1 and is blocked by tetrac, acting at
avb3. Acetylation of the receptor is another intranuclear event that prepares TR for recruitment of a
nuclear co-activator such as p300.
Certain of the foregoing observations have led to recognition of overlapping cellular effects of
thyroid hormone and estrogen and of their genomic and nongenomic mechanisms of action. For
example, T4 can, via avb3, cause proliferation of ERa-expressing breast cancer (MCF-7) cells [1] and
lung cancer cells [2]. The proliferative effect is ER-requiring and occurs in the complete absence of
estrogen. Thyroid cancer cells may express ERa and -b [3,27e29]. Estradiol may support in vitro pro-
liferation of such cells, and ERa appears to be involved in growth of papillary thyroid cancer [28,29].
The progesterone receptor may also be expressed by thyroid carcinoma cells [30]. It has not been
determined whether thyroid hormone can act via ER to stimulate proliferation of thyroid cancer cells,
but integrin avb3 does mediate a proliferative effect of T4 on differentiated thyroid cancer cells [24].
A number of these actions of thyroid hormone are summarized schematically in Fig. 1.
Possible clinical consequences of the overlap of genomic and nongenomic actions of thyroid
hormone
Acting via avb3 at the plasma membrane, T4 may inﬂuence genomic events within the cell. Until
this pathway was recognized, T4 was seen almost exclusively as a prohormone and source of T3 for
control of thyroid hormone actions that were genomic. Effects of T4 on the state of cellular actin [31,32]
and on plasma membrane ion pump activity in enucleate cells, such as erythrocytes [10], had been
reported but did not involve gene expression. Because T4 is now seen to be capable of modulating
genomic events, the use of T4 clinically in mild excess to suppress endogenous pituitary thyrotropin
(TSH) may have genomic consequences, such as support of tumor cell proliferation [33] or expression
of HIF-1a or of ERa in tumor cells in which these genes are relevant to survival or proliferation.
In the patient with subclinical hypothyroidism and active cancer, the question of how aggressive to
be with T4 replacement may be asked. Subclinical hypothyroidism induced by tyrosine kinase in-
hibitor treatment of renal cell carcinoma patients is associated with a favorable response to TKI
Fig. 1. Schematic of selected overlapping nongenomic and genomic actions of thyroid hormone. Nongenomic actions of T4 and T3 are
shown to begin at the hormone receptor on heterodimeric integrin avb3 at the top of the ﬁgure. Actions labeled 1 indicate that from
the integrin receptor the hormone can regulate the state of the actin cytoskeleton via a mechanism involving a TRa isoform. From
avb3 the hormone can also drive intact cytoplasmic TRa1 (TRa in the ﬁgure) into the nuclear compartment. T3 acts locally in the
plasma membrane to modulate activity of the plasma membrane Naþ/Hþ exchanger, but the hormone may act genomically to cause
transcription of the exchanger gene. Similarly, T3 acts locally to increase function of plasma membrane Naþ, Kþ-ATPase via phos-
phatidylinositol 3-kinase (PI3K/Akt/PKB), but the hormone also genomically affects transcription of the sodium pump gene. In
actions labeled 2, thyroid hormone nongenomically drives cytoplasmic TRb1 and ERa into the cell nucleus, each in a complex with
activated MAPK (pMAPK; pERK1/2). Nuclear TR is partially readied for transcriptional activitydi.e., prepared to act genomi-
callydwhen, in response to nongenomic signaling from hormone at avb3, it sheds corepressors and attracts coactivator proteins and
is able to bind nuclear T3. Actions labeled 3 are traditional genomic actions of T3, in which the hormone gains access to the nucleus
and is bound by TR to complete generation of transcriptionally active receptor-hormone-coactivator complexes.
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coworkers have improved survival by reducing circulating endogenous T4 levels with low-dose
thiourea administration and exogenous T3, maintaining clinical euthyroidism exclusively with T3
[36]. Medically induced subclinical hypothyroidism in a prospective study prolonged survival in
endstage glioblastoma patients [37]. Such reports are consistent with actions of T4 initiated non-
genomically at avb3 that support complex tumor cell proliferation and pro-angiogenic activities that
downstream of the integrin depend upon gene transcription but do not involve TRs. L-thyroxine (T4) is
primarily cited in these cancer cell observations because, as pointed out above, the afﬁnity of the
hormone receptor on avb3 favors T4 over T3 [19], and studies of cancer cell proliferation have shown
T3 to be active only at supraphysiologic concentrations, whereas T4 is active at physiologic free hor-
mone levels [2,14].
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cancer cells [1] raises the possibility that, in post-menopausal women, recurrent tumor may be
expressing stimulation by endogenous thyroid hormone. Interestingly, in vitro studies have shown that
fulvestrant will block the proliferative effect of T4 in ERa-expressing breast tumor cells [1]. However,
little clinical information is available about the utility or not of inducing euthyroid hypothyroxinemia
[36] or subclinical hypothyroidism in this patient population. As noted above, a possible link may exist
between endogenous estrogen and behavior of ER-expressing thyroid cancer.Practice points
Acting nongenomically at the cell surface, L-T4 can support cancer cell proliferation and tumor-
related angiogenesis.
 In the patient with endstage cancer and euthyroidism, a therapeutic goal to be considered is
reduction in circulating T4 (euthyroid hypothyroxinemia) with low-dose methimazole and L-
T3 administration.
 In the postmenopausal patient with an ERa-expressing cancer of breast, ovary or lung,
endogenous T4 may act via integrin avb3 to mimic, downstream, the action of estrogen at the
estrogen receptor. Euthyroid hypothyroxinemia is an option.
Research agenda
 Develop and clinically test pharmacologic inhibitors of the thyroid hormone receptor on
integrin avb3 for management of a) advanced cancer or b) nonmalignant states in which
uncontrolled angiogenesis contributes to disease expression.
 Extend evaluation of induced euthyroid hypothyroxinemia in cancer to prospective trials in
patients with endstage cancer.Overlapping genomic and nongenomic actions of steroid hormones
Estrogen
One of the earliest reported examples of rapid, extranuclear signaling by estradiol was by Clara
Szego and June Davis in 1967. Ovariectomized rats were treated with intravenous estradiol, which led
to a very rapid (within 15 s) upregulation of uterine cAMP [38]. These observations suggested that
estrogen might be triggering rapid activation of a G protein within the uterine tissue, and that this in
turn might regulate important estrogen-mediated physiologic responses. While Szego, Davis, and
others continued to study this phenomenon for several decades, it was not until the late 1990s and
2000s that extranuclear steroid signaling became an accepted concept within the general steroid
signaling community. Part of this acceptance came from the recognition that steroids such as estrogen
promote rapid phosphorylation and then recruitment of steroid receptor coregulators to intranuclear
transcriptional signaling complexes, thus indicating that rapid kinase signaling must be not only
associated with, but likely required, for normal transcriptional signaling. Accordingly, several groups
have demonstrated rapid (within minutes) estrogen-triggered G protein and kinase activation in a
myriad of cell types including but not limited to breast cancer cells, uterine cells, lung cancer cells, and
endothelial cells [39,40].
After conﬁrming that rapid estrogen-triggered signals occur, the next step was to identify the re-
ceptor regulating these events. Notably, some evidence suggests that estrogen might be capable of
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coupled estrogen receptor 1” (GPER) [41e43]. However, mice lacking GPER have relatively normal
reproductive function with no obvious alterations in known estrogen-dependent processes [44]; thus
the physiologic importance of GPER is still in question. In contrast, a vast body of work focusing on the
classical estrogen receptors (ERa and ERb) has shown that approximately 5% of these molecules
localize in the membrane (primarily full length estrogen receptor, but possibly splice variants as well)
and regulate the majority of known extranuclear estrogen responses [39,40,45e50]. This membrane
localization is regulated by two likely related mechanisms. First, ERa directly interacts with caveolin
proteins (primarily caveolin 1) and therefore co-localizes with these molecules in lipid rafts within the
membrane [50e52]. Second, Marino discovered and then Levin further characterized a palmitoylation
site on ERa within a region dubbed the “E domain” that is required for membrane targeting of the
protein [53e55] (see Fig. 2).
Once targeted to the membrane, ERa and ERb trigger a number of extranuclear responses. Here we
will focus on ERa. As mentioned, Szego and colleagues reported rapid changes in cAMP in response toFig. 2. Overview of estrogen receptor (ERa) signaling. ERa is localized to lipid rafts within the plasma membrane through palmi-
toylation as well as interactions with caveolin 1 (Cav1). Estrogen stimulation of the receptor leads to G protein activation as followed
by transactivation of the EGF and IGF receptors. EGF receptor transactivation involves matrix metalloproteinase (MMP)-mediated
release of EGF receptor ligands, while IGF receptor transactivation is less well understood. Both G protein signaling and receptor
tyrosine kinase transactivation lead to PI3K activation, which subsequently activates eNOS in endothelial cells. In addition, PI3K and
MAPK activation promote phosphorylation of coregulators, as well as perhaps direct phosphorylation of ERa, leading to increased
ERa-mediated transcription and subsequent protein synthesis. Thus nongenomic and genomic ERa signaling are tightly linked.
Notably 27-hydroxycholesterol (27 HC) can inhibit ERa signaling in endothelial cells to prevent blood vessel repair, but also can
promote ERa signaling in other cells to increase inﬂammation in cardiovascular disease and to stimulate breast cancer tumor growth.
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that estradiol rapidly modulates G protein signaling in several different cell types [39,40]. Shaul and
colleagues isolated a speciﬁc region within ERa that binds directly to G proteins within the plasma
membrane of endothelial cells to regulate their signaling [56e60]. Physiologically, these interactions
are critical for estrogen-induced eNOS expression in endothelial cells, which in turn regulate important
functions such as wound healing. Thus, one mechanism whereby estrogen may be cardioprotective in
youngerwomen is that it can improve blood vessel repair via extranuclear signaling through G proteins
(Fig. 2).
In addition to regulating G protein signaling, estrogens also trigger rapid kinase signaling via
membrane-localized ERa. The consensus model is that estrogen binding to membrane ERa promotes
rapid activation of growth factor receptors through matrix metalloproteinase (MMP)-mediated release
of membrane-associated growth factor receptors ligands. Speciﬁc growth factor receptors that have
been shown to be activated include the epidermal growth factor receptor (EGFR) and the insulin-like
growth factor receptor (IGFR) [61,62]. Once activated, these growth factor receptors trigger activation
of Akt, ERK, and other kinase signals. Like estrogen-induced G protein signaling, estrogen-triggered
activation of kinase signaling has proven to be similarly critical for wound healing [63] (Fig. 2). Also,
via ERb, estrogen-induced kinase signaling appears to be an important mediator of normal cardiac
function [64,65], again demonstrating the importance of extranuclear estrogen signaling in cardio-
vascular health. Finally, extranuclear kinase signaling, as well as G protein signaling, has been shown to
be an important promoter of breast cancer cell proliferation [62,66], demonstrating another pathway
(and potential target) that estrogen utilizes to promote breast cancer growth.
Estrogen is not the only ligand that can trigger rapid, transcription-independent ERa-mediated
responses. Studies from the Shaul laboratory demonstrate that the cholesterol metabolite 27-
hydroxycholesterol (27 HC) blocks estrogen-mediated blood vessel repair through inhibition of ERa-
mediated extranuclear signaling. In addition to having antagonistic properties, 27 HC can also be an
agonist for ERa, promoting worsening atherosclerosis by triggering inﬂammatory responses via ERa-
dependent signals [67e69]. Since 27 HC and cholesterol levels are correlated, these studies suggest that
hyperlipidemia may have adverse effects on cardiovascular disease through actions with ERa. Finally,
27 HC has been shown to promote breast cancer cell growth via ERa [70]. 27 HC appears to be syn-
thesized in MCF7 breast cancer cells and is upregulated in breast cancer samples from patients,
indicating that local production of 27 HC might promote progression of ER-positive breast cancer.
While both extranuclear and intranuclear estrogen signaling are known to promote important
physiologic responses, how these two signals were connected to one another remained controversial
until very recently. Taking advantage of the palmitoylation site that is required for membrane locali-
zation and therefore membrane signaling of ERa, two groups created an ERa knock-in mouse whereby
the wild-type ERa gene was replaced with a mutated gene encoding an estrogen receptor that lacked
the palmitoylation site and therefore was not capable of extranuclear signaling [71,72]. With only a few
exceptions, these “nuclear-only estrogen receptor” (NOER) female mice look very much like the global
ERa knockout mouse, with reduced mammary size, small uteri, infertility, and other signs of hypo-
gonadism. These observations suggest that extranuclear ERa signaling is required for normal nuclear
ERa signaling in vivo, and that these two processes are lineardstarting with extranuclear kinase signal
and ending with changes in transcription. The membrane-only estrogen receptor (MOER) knock-in
mouse also looked similar to the global ERa knockout, conﬁrming that just as ERa-mediated nuclear
signaling alone is not sufﬁcient to generate normal estrogen responses, ERa-mediated extranuclear
signaling alone is also not sufﬁcient to drive these estrogen responses [73]. In short, both extranuclear
and nuclear estrogen signaling appear to be required for themajority of important physiologic estrogen
functions, including fertility, breast development, and bone metabolism.
Androgen
While a tremendous amount of research from multiple laboratories has focused on the interplay
between extranuclear and nuclear estrogen signaling, similar studies focused on androgen signaling
have been more limited. However, many similarities between classical estrogen and androgen re-
ceptors are notable. First, the androgen receptor (AR) is palmitoylated, which regulates its localization
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within the membrane [74]. Third, androgen activation mediates rapid G protein signaling via the
membrane-localized AR [75e78]. Finally, androgen activation of membrane-localized AR leads to rapid
transactivation of the EGF receptor via a MMP-mediated release of EGF receptor ligands, after which
both Akt andMAPK pathways are activated, the latter of which is important for subsequent nuclear AR-
mediated signaling [79e83] (Fig. 3).
Work over the last decade has uncovered a novel regulator of both extranuclear and nuclear
androgen signaling: paxillin. Paxillin is normally described as a primarily cytoplasmic scaffolding
molecule that regulates a myriad of cytoplasmic functions that include kinase signaling, integrin
signaling, cytoskeletal rearrangements, and cellecell adhesion [84e87]. However, several studies now
demonstrate that paxillin plays an additional role in regulating androgen signaling both in the cyto-
plasm and in the nucleus [81,82,88,89]. Surprisingly, paxillin's importance in androgen signaling was
ﬁrst discovered in oocytes from Xenopus leavis. For over 50 years, steroids have been known to trigger
meiotic re-entry in oocytes (often called “maturation”) [77]. Since meiosis occurs completely inde-
pendent of transcription, steroid-triggered oocyte maturation is therefore an outstanding example of aFig. 3. Nongenomic androgen receptor (AR) signaling enhances genomic AR signaling. Androgen stimulates ARs that are localized to
lipid rafts within the plasma membrane through palmitoylation as well as interactions with caveolin 1 (Cav1). AR activation at the
membrane leads to matrix metalloproteinase (MMP)-mediated transactivation of the EGF receptor (EGFR) via release of EGF receptor
ligands. EGF receptor signaling then activates downstream PI3K and MAPK signaling. The latter is dependent on paxillin. Once
activated ERK1/2 promotes phosphorylation of paxillin on serine residues, leading to the nuclear localization of phosphopaxillin
(pPaxillin). Once in the nucleus, pPaxillin retains androgen-bound AR in the nucleus, where the AR can promote gene transcription
and subsequent protein synthesis. Thus paxillin is a critical regulator of both genomic and nongenomic AR signaling, and serves as a
liaison between cytoplasmic and nuclear events.
S.R. Hammes, P.J. Davis / Best Practice & Research Clinical Endocrinology & Metabolism 29 (2015) 581e593 589physiologically relevant, purely nongenomic steroid-triggered process. Furthermore, since androgens
appear to be physiologic mediators of Xenopus laevis oocyte maturation [90], this system serves as an
excellent model for studying extranuclear androgen signaling. Using this model system, studies have
shown that just as estrogens regulate G protein and kinase signaling in somatic cells, androgen-
induced oocyte maturation requires rapid changes in G protein signaling as well as activation of
MAPK signaling [75,78,91e93]. Notably, a key regulator of androgen-triggered kinase signaling in
oocytes is paxillin because knockdown of its expression abrogates steroid-triggered kinase signaling
and downstream maturation [89]. Studies in oocytes have implicated ERK-mediated phosphorylation
of serine residues within paxillin as important regulators of ooctyes' maturation downstream of ERK
signaling becausemutating these serines to alanines results in a paxillinmolecule that can still mediate
androgen-induced ERK activation, but is unable to mediate subsequent meiotic resumption. Thus, in
essence, paxillin is both upstream and downstream of ERK signaling and plays an important biological
role in regulating meiosis.
Based on the aforementioned work in frog oocytes, investigators have been able to demonstrate
that paxillin is also a critical regulator of prostate cancer growth in humans [81,82]. In several human
prostate cancer cell lines, paxillin is similarly found to be required for ERK signaling, which in turn
regulates phosphorylation of human paxillin on serine residues similar to those present in the frog
isoform. This serine phosphorylation event then promotes nuclear localization of phosphoserine-
paxillin, where it interacts with nuclear AR to retain it in the nucleus and to support AR-mediated
transcription of a number of endogenous prostate genes (Fig. 3). As with the frog paxillin, mutation
of these serine phosphorylation targets to alanines completely abrogates androgen-mediated tran-
scription, while androgen-induced ERK signaling still occurs normally. In the absence of phosphory-
lated paxillin, prostate cancer growth, migration, and invasion are markedly attenuated. Finally,
paxillin expression is elevated in human prostate cancer samples, suggesting that nongenomic
androgen actions may be upregulated in prostate cancer. Thus, in its capacity as a liaison between
extranuclear and nuclear androgen signaling, paxillin appears to be a critical regulator of androgen-
triggered prostate cancer progression and may serve as a useful marker of prostate cancer aggres-
siveness or perhaps even as a potential target for prostate cancer therapy.
Finally, paxillin actions are not just important for AR signaling in prostate cancer cells. Recent work
demonstrates that ARs similarly use both extranuclear and nuclear pathways to regulate ovarian fol-
licle development by both inhibiting follicle atresia and also promoting FSH-mediated follicle growth
[83]. With extranuclear and nuclear androgen signaling, both of which are mediated by paxillin, fol-
licles do not grow appropriately, and fertility is compromised. Thus, besides regulating pathologic
androgen-mediated growth in prostate cancer, paxillin is also an important regulator of normal
androgen-regulated physiologic processes such as female fertility.
With regard to paxillin's importance in ERa-mediated signaling, just as paxillin levels are upre-
gulated in prostate cancer samples, paxillin levels are also upregulated in some aggressive Her2 pos-
itive breast cancers [94]. Therefore, as seen in prostate cancer, paxillinmay be an important regulator of
breast cancer progression. However, on a molecular level, while paxillin may be playing a small role in
modulating extranuclear estrogen signaling [95], its role in regulating estrogen-mediated transcription
remains unclear.
Possible clinical consequences of overlapping genomic and nongenomic actions of steroids
The clinical consequences of overlapping genomic and nongenomic actions with steroid hormones
are myriad. Cardiovascular protection by estrogen appears to require both extranuclear (via G proteins
and kinases) and nuclear (via transcription) ERa actions. In the example of cardiovascular disease, non-
nuclear ERa may actually dominate, both in a positive way in response to estradiol and in a negative
way in response to 27 HC. Through local production, both estradiol and 27 HC may use overlapping
nongenomic and genomic actions of ERa to promote breast cancer growth in ER-positive tumors.
Knock-in mouse models where nuclear and extranuclear ERa actions are clearly isolated from one
another demonstrate that nearly all of the important known actions of estrogens in the pituitary, ovary,
uterus, and mammary glands require both genomic and nongenomic ERa signaling. These studies are
crucial because they are the ﬁrst to use genetic mouse models to clearly show the physiologic
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signaling, studies both in prostate cancer and in the ovary demonstrate the sequential nature of
extranuclear and nuclear AR signaling and implicate paxillin as an important liaison between these two
cellular compartments. Since paxillin expression is upregulated in prostate cancer and in some
aggressive breast cancers, this molecule may serve as an important biomarker for tumor aggressive-
ness as well as a potential target for the treatment of hormone-dependent cancers.Practice points
 Integration of extranuclear and nuclear steroid signaling plays a critical role in many
important physiologic processes, including fertility, cardiovascular function, and growth of
hormone dependent cancers.
 Cholesterol metabolites such as 27-hydroxycholesterol can signal through the estrogen re-
ceptor to worsen atherosclerosis, inhibit wound repair, and possibly promote breast cancer
growth.
 Balanced androgen signaling in the ovary is critical for normal female fertility e too little or
too much androgen signaling leads to reduced follicle development and ovulation.
Research agenda
 Develop novel therapies to target the integration of nuclear and extranuclear signaling in
steroid-dependent cancers of the prostate and breast.
 Improve our understanding of how cholesterol metabolites regulate cardiovascular disease
so that we can potentially manipulate their levels in a therapeutically advantageous manner.Conclusions
Recent reports have demonstrated that nongenomic and genomic signaling by both thyroid hor-
mones and steroids are inextricably linked, such that most important transcriptional changes in
response to these hormones require both processes to be functioning normally. Nongenomic signaling
canarise fromclassical “nuclear”hormonereceptorsonornear the cell surface and fromother important
cell membrane signaling molecules such as avb3. These nongenomic signals can modulate nuclear
transcriptionviamany pathways, including nuclear localization of classical nuclear receptors or changes
in phosphorylation of important nuclear signaling molecules. Understanding how genomic and non-
genomic signaling work together to regulate important biological processes will help us better design
novel means of regulating these processes and therefore may improve our ability to treat hormone-
dependent cancers such as breast and prostate cancer, as well as other tumors such as lung cancer.
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